Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M versus TRAVASOL 10 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M versus TRAVASOL 10 W O ELECTROLYTES.
AMINOSYN II 3.5% M vs TRAVASOL 10% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids for protein synthesis, serving as substrates for anabolic processes in parenteral nutrition.
Travasol 10% w/o electrolytes is a parenteral nutrition solution containing essential and non-essential amino acids. The amino acids provide substrates for protein synthesis, thereby supporting tissue repair, growth, and maintenance. The solution also provides a source of nitrogen and caloric replacement.
Intravenous infusion of 1.2 to 2.2 g amino acids per kg per day, adjusted to meet metabolic and nutritional requirements. Typical adult dose: initial infusion rate of 50 mL/hour, increasing to 125 mL/hour (4.4 g amino acids per hour) based on tolerance. Not for direct peripheral administration without supplementation of electrolytes and/or dextrose.
10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.
None Documented
None Documented
The terminal elimination half-life of amino acids from the infusion mixture is not uniformly defined; however, individual amino acids have half-lives ranging from 10 to 30 minutes. For the mixture, the effective half-life is clinically considered to be approximately 1-2 hours, reflecting rapid metabolic clearance. In renal impairment, the half-life may be prolonged due to reduced urea clearance.
The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Aminosyn II 3.5% M is a crystalline amino acid solution. Amino acids are primarily eliminated by metabolic utilization for protein synthesis and energy production. Excess amino acids undergo deamination, with nitrogen excreted as urea in urine via renal route. Fecal and biliary excretion are negligible. Approximately 80-90% of infused nitrogen is recovered as urea in urine in patients with normal renal function.
Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution